Publication

ISTH •
14 July, 2026 •
•

Joint Health Outcomes With Efanesoctocog Alfa Prophylaxis for Patients With Severe Hemophilia A: Third Interim Analysis of the Phase 3 XTEND-ed Study

Christoph Königs, Annette von Drygalski, Cedric Hermans, Barbara A. Konkle, María Teresa Álvarez Román, Liane Khoo, Nobuaki Suzuki, Graham Neill, Linda Bystrická, Meredith Foster, Elena Santagostino, Sriya Gunawardena, Robert Klamroth

Available materials

Poster

Publication

ISTH •
14 July, 2026 •
•

Baseline Characteristics of Patients Switching to Prophylactic Efanesoctocog Alfa Therapy Evaluated for Joint Health in Hemophilia A in Taiwan (PROTECT-ALT Study)

Yeu-Chin Chen, Ming-Ching Shen, Cheng-Wei Huang, Hung Chang, Jiaan-Der Wang, Sheng-Chieh Chou, Ching-Tien Peng, Chih-Cheng Hsiao, Chia-Yau Chang, Te-Fu Weng, Tong-Ling Chien, Ching-Min Chang, Shyh-Shin Chiou

Available materials

Poster

Publication

ISTH •
14 July, 2026 •
•

Interim analysis of the A-MORE real-world study: 4-year treatment outcomes with a recombinant factor VIII Fc in the overall and non-severe populations

Jan Astermark, Antonio Coppola, Swee Wenning, Ruben Berrueco, Ester Zapotocka, Andreu Schoenenberger López, Eva Bednar, Stefan Lethagen

Available materials

Poster

Publication

Perioperative management of Haemophilia B: A HaemSTAR UK-wide audit

Joint Health Outcomes With Efanesoctocog Alfa Prophylaxis for Patients With Severe Hemophilia A: Third Interim Analysis of the Phase 3 XTEND-ed Study

Baseline Characteristics of Patients Switching to Prophylactic Efanesoctocog Alfa Therapy Evaluated for Joint Health in Hemophilia A in Taiwan (PROTECT-ALT Study)

Interim analysis of the A-MORE real-world study: 4-year treatment outcomes with a recombinant factor VIII Fc in the overall and non-severe populations

Plain Language Summary: What is Extravascular Distribution of Factor IX and how does it Affect Management of Those with Haemophilia B?

Real-World Effectiveness and Usage of rFIXFc in Haemophilia B: Final Paediatric Data from the B-MORE Study

Real-World Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B by Age Groups: Final B-MORE Study Data

Extravascular distribution of factor IX: evidence and relevance for hemophilia B replacement therapy